Dissertations / Theses on the topic 'Adenovirus diseases'

p53 is a pivotal tumour suppressor in mammalian cells. It protects the integrity of a number of cellular pathways, preventing the malignant transformation of cells. There is however perhaps nothing more efficient at disrupting cellular pathways than a virus. Viruses infiltrate cells commandeering the normal growth and survival pathways for their narcissistic needs. While the association between viral infections and the induction of p53 has long been recognised, there is controversy surrounding the ultimate role of p53 during a virus infection. The classical model of p53 in an adenovirus infection is that p53 is a formidable obstacle which needs to be overcome. Adenoviruses overcome p53 by degrading the protein and removing its ability to transactivate its target genes. However the degradation is not immediate and there is increasing evidence which would suggest p53 is actually beneficial to an adenovirus infection. In the introductory chapter, I review what is known about p53 and virus infections. What emerges from this review is the sheer number of interactions that occur between viruses and p53, indicating its importance in an infection. Additionally it shows that adenoviruses are not the only virus shown to benefit from the presence of p53. What beneficial role p53 may be fulfilling in an adenovirus infection is unclear. The experiments reported in this thesis investigate the functions of p53 in an adenovirus infection. In Chapter Three, immunoblots on a panel of adenovirus infected cells reveal that p53 levels do not correlate with the level of the classical p53 target proteins. This indicates that p53 is disconnected from its target genes during an infection. Promoter/reporter assays carried out on infected cells show that adenovirus can directly regulate p53 target genes independently of p53. In Chapter Five, I show this regulation is dependent on E1a, with transient transfection of E1a resulting in the marked activation of p53 target promoters. E1a mediated transactivation appears to be reliant on the largest splice variant of E1a (E1a-289R) and the presence of pRB. Electrophoresis mobility shift assays reveal that the transcription factor Sp1 is involved. In Chapter Four, p53 transcription in an adenovirus infection was directly assayed by using an artificial p53 consensus response element. The results show that p53 is unable to activate its consensus response element during an infection. However, I show that p53 is transcriptionally competent in an infection, and is able to transactivate a mutant derivative of the p53 consensus sequence. This shows that p53 is not only transcriptional competent but has a gain-of-function in an infection. This gain-of-function requires E1a, and appears not to be due to a change in the DNA binding affinity of p53. The data in this thesis show that adenoviruses not only appear to inhibit and control the normal transcriptional profile of p53 but appear to modify p53, giving it a new transcriptional profile. This provides a possible mechanism by which p53 could aid an adenovirus infection.

CAR (for C&barbelow;oxsackievirus and A&barbelow;denovirus R&barbelow;eceptor) is a novel member of the Ig superfamily, which has recently been identified as a high affinity receptor for both Coxsackievirus and certain adenovirus (AV) serotypes. Virus bound by CAR is believed to be passed to integrins which bind an RGD (Arg-Gly-Asp) sequence in the viral penton base protein and act as secondary receptors responsible for virus internalization.
Recent studies have shown that, in integrin-expressing cells, CAR-mediated AV uptake does not require the cytoplasmic (CP) domain of CAR, presumably because virus bound to the CAR extracellular (EC) domain can be passed to integrins for subsequent internalization. It has however also been reported that CAR can directly mediate AV uptake in the absence of penton base RGD-alphav integrin interactions. I therefore attempted to determine whether the CP domain of CAR is required for CAR-mediated AV uptake in cells which do not express integrins, or in which integrin function has been blocked by RGD-containing peptide.
As CAR is the primary AV receptor and integrins are secondary AV receptors I investigated the possibility that these proteins associate in a functional complex in the cell membrane. (Abstract shortened by UMI.)

Abstract Adenoviral gene transfer is a valuable tool in molecular biology research. In order to be an efficient and safe vector, adenovirus structure and infection mechanism as well as molecular biology of the used transgene need to be well studied. The aim of this study was to evaluate the role of adenovirus as a gene transfer vector from several perspectives. Adenovirus uses receptor-mediated endocytosis in order to enter the target cell. The effect of Rab5 GTPase on adenovirus entry and gene transfer efficiency was examined first. Next, adenovirus was used as an investigatory tool in the cardiovascular research, focused on clarifying the role of adrenomedullin (AM) in heart and vascular remodeling. Finally, a model of adenoviral gene transfer into skin fibroblasts was used. The role of Rab5 GTPase in the adenovirus endocytosis was examined in HeLa cells using Cy3-labeled adenovirus, and gene transfer efficiency using β-galactosidase encoding adenovirus. Rab5 increased both adenovirus uptake and gene transfer, whereas dominant negative Rab5S34N decreased both endocytosis and gene transfer. The data indicate that Rab5 is needed in mediating the adenovirus uptake into the target cell. In the rat heart, adenovirus-mediated AM gene transfer transiently improved systolic function both in vivo and in vitro. AM caused activation of translocation of protein kinases C ε and δ, whereas phosphorylation of p38 mitogen activated protein kinase was decreased in the left ventricle. AM significantly attenuated the development of angiotensin II-induced cardiac hypertrophy. In rats with myocardial infarction, AM enhanced dilatation of left ventricle and thinning of anterior wall. The role of AM in neointima formation was evaluated in rat artery after endothelial injury. Intravascular AM gene transfer decreased neointimal growth and increased neointimal myofibroblasts apoptosis. These results show that AM regulates left ventricular systolic function and remodeling in the heart, and plays a role in pathological vascular remodeling. Adenovirus-mediated lysyl hydroxylase (LH) gene transfer into skin fibroblasts of type VI Ehlers-Danlos syndrome patient and rat skin increased functional LH production, elevated LH activity, and human LH mRNA production both in vitro and in vivo. LH gene replacement therapy may thus lead to possibilities to improve skin wound healing in Ehlers-Danlos syndrome patients.

Replication-deficient adenovirus (Ad) and modified vaccinia virus Ankara (MVA) vectors expressing single Plasmodium falciparum antigens can induce potent T cell and antibody responses and have entered clinical testing using a heterologous prime-boost immunisation approach (Ad_MVA). This thesis describes a number of pre-clinical approaches aimed at enhancing the efficacy of these viral vectored vaccines targeting the blood-stage of malaria. First, the development of a highly efficacious malaria vaccine is likely to require a multi-antigen and/or multi-stage subunit vaccine. The utility of an Ad_MVA immunisation regime combining vaccines expressing the 42kDa C-terminus of the blood- stage antigen merozoite surface protein 1 (MSP142) and the pre-erythrocytic antigen circumsporozoite protein (CSP) in the P. yoelii mouse model was investigated. It was found that vaccine co- administration leads to maintained antibody responses and efficacy against blood-stage infection, but reduced secondary CD8+ T cell responses and efficacy against liver-stage infection. CD8+ T cell interference can be minimised by co-administering the MVA vaccines at separate sites, resulting in enhanced liver-stage efficacy. The mechanisms of CD8+ T cell interference were explored. Second, Ad_MVA regimes expressing blood-stage antigens that can protect against P. chabaudi and P. yoelii blood-stage infection were tested against P. berghei, but did not confer protection. Similarly, IgG from rabbits immunised against P. falciparum MSP1 (PfMSP1) could not protect mice from a chimeric P. berghei parasite expressing PfMSP1. Third, two molecular adjuvants, the C4bp α-chain oligomerisation domain (IMX108/313) and the Fc fragment of murine IgG2a, were tested for their ability to enhance immunogenicity of recombinant adenoviruses when fused at the C-terminus of a blood-stage antigen. IMX108/313 was found to adjuvant T cell responses of small (< 80kDa) antigens and this was associated with antigen oligomerisation. However, the Fc fragment did not adjuvant responses. Finally, it was found that using a strong early promoter to drive antigen expression enhances the immunogenicity of single administration MVA vaccines, but that this did not enhance post-boost immunogenicity in an Ad_MVA regime.

Les pathogènes neurotropiques représentent une banque d’outils biologique afin de cibler spécifiquement le système nerveux central (SNC), pour son étude mais aussi dans l’optique d’une thérapie. Parmi eux, l’adénovirus canin de type 2 (CAV-2) est un vecteur prometteur pour cibler le SNC. CAR a été principalement étudié en tant que récepteur viral. Cependant, plusieurs études montrent que CAR est essentiel dans le développement du cœur ainsi que du système lymphatique. De manière intéressante, CAR est fortement exprimé pendant le développement du SNC, suggérant un rôle dans l’établissement des réseaux neuronaux. Dans ce travail, nous avons confirmé que CAR est lié aux mécanismes d’endocytoses et au trafic intracellulaire. L’endocytose de CAR est ligand dépendant. La partie intracellulaire de CAR régule son endocytose. Nos données suggèrent que CAR est l’unique récepteur pour CAV-2. Le présent travail de recherche montre aussi que CAR ne semble pas participer à la formation du SNC. En revanche, au niveau du SNC mature, CAR est impliqué dans la plasticité synaptique, dans la neurogénèse adulte et participe à l’homéostasie des synapses, mécanismes impliqués dans les processus mnésiques
The coxsackievirus and adenovirus receptor (CAR) is a single-pass transmembrane protein belonging to the CTX subfamily of the immunoglobulin superfamily. CAR has been extensively studied as a viral receptor for coxsackie B viruses and some adenoviruses (AdVs). CAR is essential for the development of the cardiovascular and lymphatic system. Interestingly, CAR is highly expressed in the developing brain and has been hypothesized to regulate the establishment of the neuronal networks. In my PhD work, I showed that CAR can be link to the endocytic pathways and intracellular trafficking. CAR endocytosis is ligand-dependent and is regulated by CAR intracellular domain (ICD), suggesting strongly that CAR is most likely the unique receptor for canine adenovirus type 2 (CAV-2). Moreover, we demonstrated that CAR depletion in the developing brain did not significantly perturb brain development. In the healthy adult brain, CAR is relatively abundant and we demonstrated that CAR loss of function affected hippocampal plasticity, adult neurogenesis and synapse homeostasis, which affect cognition

Der Coxsackievirus- und Adenovirusrezeptor (CAR) ist ein Typ I Transmembran-protein, das an der Adsorption von Viren und der Aufrechterhaltung von Zell-Zellkontakten beteiligt ist. Coxsackievirus B3 (CVB3) Infektionen sind eine häufige Ursache für akute Myokarditis, die bei Patienten häufig zu chronischer Kardiomyopathie bis zur Herzinsuffizienz führen können. CAR ist für die Aufnahme von Viren in unterschiedliche Zelltypen verantwortlich und damit ein potentielles Ziel bei der Therapie und Prävention von CVB3-Infektionen. Der komplette Knockout von CAR ist embryonal letal. Die betroffenen Embryonen zeigten Missbildungen des Herzens. Weiterhin konnte eine reduzierte Expression von Connexinen im Knockout beobachtet werden – ein mögliches Zeichen gestörter interzellulärer Kommunikation. In konditionellen CAR Knockout Tieren führte die Infektion mit CVB3 im Gegensatz zu CVB3-infizierten Wildtyp Kontrolltieren zu keinen pathologischen Veränderungen oder eine Erhöhung von Entzündungsmarkern. Die kontraktile Funktion des CVB3-infizierten Knockout Herzen war erhalten. Um mögliche unerwünschte Konsequenzen aus dem Verlust von CAR zu untersuchen, wurde eine umfassende kardiale Phänotypisierung durchgeführt, die AV-block im Knockout-Herzen zeigte. Der zugrunde liegende Mechanismus betrifft die Interaktion von Tight- und Gap-Junctions mit veränderter Expression und Lokalisierung von Connexinen, sowie die interzelluläre Kommunikation zwischen CAR-Knockout Kardiomyzeten. CAR ist essentiell für eine normale Embryonalentwicklung und kardiale Funktion. Das CAR-Knockout-Modell bietet einerseits den ersten genetischen Hinweis für eine Rolle von CAR als Virusrezeptor in vivo und belegt andererseits die Relevanz von direkter Virus-vermittelter Symptomatik gegenüber einer sekundären autoimmun- Komponente in CVB3-induzierten Herzerkrankungen. Damit ist CAR ein potentielles therapeutisches Target in der Prävention und Behandlung von viraler Myokarditis.
The coxsackievirus and adenovirus receptor (CAR) is a type I transmembrane protein involved in virus uptake and the maintenance of cell-cell contacts. Coxsackievirus B3 (CVB3) infections are frequent causes of human acute myocarditis, often resulting in chronic cardiomyopathy that may progress into terminal heart failure. The coxsackievirus and adenovirus receptor (CAR) is involved in virus uptake into various cell types and has therefore been suggested as a therapeutic target to prevent or treat CVB3 induced diseases. The complete CAR-knockout was embryonic lethal at midgestation with cardiac malformation. Connexin expression was decreased in the knockout, suggesting an abnormal cell-cell communication secondary to the loss of CAR. The role of CAR in murine viral myocarditis was investigated using the inducible CAR-knockout infected with CVB3. Unlike control animals exposed to CVB3, the cardiac inducible knockout mice did not exhibit structural changes such following CVB3 infection, or increased production of markers of inflammation, and severe contractile dysfunction. To evaluate possible adverse effects that might result from CAR deficiency, we implemented a detailed cardiac phenotyping protocol and found that CAR deficient animals developed AV nodal block. The underlying mechanism relates to the crosstalk of tight and gap junctions with altered expression and localization of connexins that affect the communication between CAR knockout cardiomyocytes. Thus, CAR is essential for embryonic development and normal cardiac function. The CAR-knockout does not only provide the first genetic evidence to establish CAR as the CVB3 receptor in vivo, but furthermore demonstrates the relevance of direct virus-mediated pathology versus a secondary autoimmune component in CVB3 induced heart disease. Our data suggest that CAR is a suitable target to help prevent and treat viral myocarditis.

Hepatitis C virus (HCV) is a major global pathogen estimated to infect over 170 million people worldwide. A recent study has shown that vaccination with adenoviral vectors, based on rare human and simian serotypes encoding the non-structural (NS) proteins of HCV, induces highly potent, multi-specific and durable T cell responses in healthy human volunteers. In this thesis I assess the safety and immunogenicity of these vaccines (ChAd3–NSmut and Ad6-NSmut), for the first time in HCV infected patients. This work also explores whether vaccine-induced T cell responses target in vivo circulating HCV antigens and common naturally occurring epitope variants. Patients with treatment naive chronic genotype 1 HCV infection were vaccinated (i.m.) with ChAd3-NSmut and Ad6-NSmut in a heterologous prime boost schedule, either with or without current IFN and ribavirin (IFN/RBV). Epitope-specific T cell responses were defined by fine mapping using HCV peptides. Circulating viral genomic sequence was determined in vaccinated patients at baseline and at any point of viral relapse. Cross-reactivity of vaccine-induced T cell responses was determined in T cell assays, using peptides corresponding to both circulating host virus and common population HCV epitope variants. An in vitro dendritic cell /T cell priming model was used to identify possible candidates for a cross-reactive vaccine immunogen at the most immunodominant epitope, NS3₁₄₀₆. 33 patients were vaccinated. Vaccination was well tolerated. At the highest vaccine dose (2.5 x 10¹⁰vp) vaccine-induced T cell responses were detectable in 11/20 patients receiving concurrent IFN/RBV and 2/4 patients receiving vaccination alone. In total 14 antigenic targets were identified, 2 of which have not previously been described. However, T cell responses were of lower magnitude and more narrowly focused than those observed in healthy volunteers vaccinated with the same regimen. Analysis of viral sequence showed that in many cases vaccine-induced T cells did not target the circulating virus. At the most immunodominant epitope (NS3₁₄₀₆), T cells induced by vaccination failed to target common circulating genotype 1 HCV variants. An in vitro model suggested that in order to target all genotype 1 sequences at this epitope, it would be necessary to insert both a genotype 1a and 1b version of this epitope into a vaccine immunogen. Vaccination with adenoviral vectors induces T cell responses in patients with chronic HCV infection, however immune responses are attenuated compared with healthy volunteers. Ultimately a successful therapeutic or prophylactic vaccine strategy will rely on inducing responses that target conserved or cross-reactive epitopes.

Nuclear factor-κB (NF-κB) is one of the main regulators of inflammatory and immune responses. It is a family of transcription factors composed of five members: RelA, RelB, cRel, NF-κB1 (p105/p50), and NF-κB2 (p100/p52). Homo- and hetero-dimers of family members are inhibited by inhibitor of &klappaB (IκB) family members and activated by IκB kinase (IKK) family members. The IKK family is comprised of IKKα, IKKΒ, and IKKγ. The focus of my dissertation delves into the role of NF-κB activation by IKKΒ in both an immunotherapy setting and its role in T cell mediated anti-tumor immune responses. A central focus of immunotherapy is to develop vaccine adjuvants that are capable of enhancing a protective adaptive immune response. Microbial adjuvants in vaccines activate key transcription factors, including NF-κB and interferon response factors (IRF). The individual role of these transcription factors in successful vaccines is not clear. We used constitutively active IKKΒ (CA-IKKΒ) expressed in an adenoviral vector (AdIKK) to determine the role of classical NF-κB activation in a vaccine-induced immune response. In an in vivo model, AdIKK induced rapid and sustained NF-κB-driven inflammation in the lungs compared to the control virus. AdIKK infection had no impact on the magnitude of T cell activation as measured by IFN-γ production; however pulmonary inflammation resulted in increased cellularity of draining lymph nodes (LN) at early timepoints resulting in increased early antibody and T cell responses. Taken together, these findings show that IKKΒ-induced NF-κB activation of an inflammatory response affects the kinetics, but not the magnitude of the adaptive immune response. NF-κB is activated in many tumor types and contributes to the progression of cancer by suppressing apoptosis, and enhancing proliferation, angiogenesis and metastasis. NF-κB is also activated in other cells within the tumor microenvironment and promotes inflammation initiated by neutrophils and macrophages. In addition to inflammatory cells, T cells can be found within the tumor microenvironment and are associated with improved patient survival. Using CA-IKKΒ, we sought to determine if NF-κB activation in tumor cells could promote T cell mediated tumor immunity. In both primary tumors and a metastatic tumor model, we found that NF-κB expression in tumors rendered immunogenic through expression of Kb-OVA led to tumor rejection or growth suppression. Tumor regression was mediated by increased CD8 T cell recruitment by chemokines. Microarray results showed increases in T cell chemokines, including CCL2 and CCL5. Knock-down of CCL2 by Lentiviral shRNA in LLC-OVA-IKK cells resulted in abrogation of tumor regression. These results suggest that NF-κB is capable of promoting immune surveillance in tumors through increased recruitment of T cells. Overall, my dissertation highlights beneficial roles of IKKΒ-induced activation of NF-κB in two separate systems: vaccine induced immune responses and tumor immune surveillance.

NF-κB and AP-1 are both redox sensitive transcription factors, and are involved in the regulation of the gene transcription of many pro-inflammatory mediators.  AP-1 and NF-κB have a close relationship with γ-glutamylcysteine synthetase (γ-GCS), the rate limiting enzyme in the synthesis of glutathione, with the γ-GCS gene containing various elements including an AP-1 binding site. Susceptibility to the effects of cigarette smoke is likely to explain why certain individuals develop COP and this susceptibility may arise from an earlier viral infection such as adenoviral infection that lies dormant, but which in the face of an oxidant stimulus such as cigarette smoke augments the inflammatory process. The in vivo studies herein have examined glutathione and γ-GCS gene transcription, oxidant/antioxidant imbalance, the redox sensitive transcription factors NF-κB and AP-1 and have assessed for the presence of the early one adenoviral protein in human lung in smokers and patients with COPD. The results how similar levels of total GSH in the lungs of patients with and without airflow obstruction, and decreased γ-GCS activity in patients with severe airflow obstruction who have undergone LVRS for emphysema compared to those with no airflow obstruction. Local lung oxidative stress as measured by malondialdehyde, and TEAC a marker of systemic oxidative stress did not correlate with lung function. DNA binding of NF-κB correlated with lung function as measured by percent predicted FEV₁, however no such relationship was found with AP-1 DNA binding. Examination for EIA gene and protein in lung tissue failed to reveal conclusive results.

La fièvre aphteuse (FMD pour Foot-and-mouth disease en anglais) est une maladie très contagieuse touchant les animaux biongulés. Elle provoque des dégâts économiques considérables sur toute la surface du globe. La fièvre aphteuse est provoquée par un virus, le FMDV. Il s'agit d'un virus à ARN simple brin, de polarité positive appartenant au genre Aphtovirus dans la famille Picornaviridae. Ce virus se réplique et se propage dans l'hôte très rapidement. Dans les zones infectées, les deux principales stratégies de contrôle utilisées sont l'abattage systématique des animaux infectés et la vaccination. A l'inverse, les vaccins ne sont pas utilisés dans les zones sans FMDV, mais l'apparition d'une épidémie nécessite des stratégies pour arrêter ou au moins limiter la diffusion du virus. Actuellement, les vaccins inactivés sont les vaccins les plus utilisés pour prévenir la maladie. Cependant, ils requièrent une production à grande échelle du virus, et malgré les mesures mises en place (laboratoire sécurisé, etc), des épidémies ont été provoquées par le passé du fait de la fuite de virus FMDV. De plus, il est difficile de distinguer les animaux infectés des vaccinés (DIVA). Il est donc nécessaire de développer de nouveaux vaccins. Au cours de l'infection, la polyprotéine du virus est clivée par des protéases virales en précurseurs structural (P1) et non structuraux (P2 et P3). La protéase 3C est responsable de la majorité des clivages ; ainsi, le précurseur P1 est clivé par la 3C en trois protéines structurales, VP1, VP3 et VP0, formant le protomère de FMDV, l'unité de base de la capside virale. La protéine VP1 joue des rôles importants dans l'attachement, la protection et le sérotypage. Du fait de la présence d'un site antigénique linéaire suffisant à la protection par production d'anticorps neutralisants, VP1 est considérée comme la protéine la plus immunogénique du virus. Dans cette étude, nous avons développé un nouveau vaccin contre la FMD, basé sur l'adénovirus canin de type 2 (Cav2). L'évaluation du transfert de gène médié par Cav2 chez le porc et le bétail in vitro montre des résultats prometteurs pour le développement de vaccins pour ces espèces, notamment l'expression des antigènes de FMDV par les candidats vaccins Cav2-FMDV. L'immunogénicité de ces candidats vaccins a été montrée chez les modèles murins et cobayes. De plus, des résultats encourageants ont été observés chez le cobaye, suggérant que la réponse immunitaire élicitée par les vecteurs recombinants pouvait conduire à une protection partielle des animaux après épreuve. Cependant, une optimisation de l'immunisation doit être faite dans le but de confirmer ces résultats. Ce type de vaccin peut de plus être utilisé comme vaccin marqueur, car il ne contient aucune protéine non structurale
Foot-and-mouth disease (FMD) is a highly contagious and economically devastating disease affecting cloven-hoofed livestock worldwide. Foot-and-mouth disease virus (FMDV) is the causative agent of FMD and one of the most infectious known animal viruses. FMDV is a positive-sense, single-stranded RNA virus belonging to the Aphthovirus genus in the Picornaviridae family. FMDV replicates and spreads in the host extremely rapidly. Slaughter and vaccination are the two major strategies used to control FMD in infected countries. In FMDV-free countries, vaccines are not used, and once the disease breaks out in these areas, strategies are required to stop or at least slow the spread of the virus. Currently, inactivated vaccines are by far the most commonly used vaccines to prevent FMD. Such vaccines, however, require large-scale production of virus, and despite the use of bio-safety facilities, vaccine production has led to inadvertent virus release and FMDV outbreak. Another limitation of inactivated vaccines is the difficulty in distinguishing between infected and vaccinated animals (DIVA). Therefore, improved vaccines need to be developed.During infection, the FMDV polyprotein is cleaved into structural (P1) and non-structural (P2 and P3) precursors by a viral protease. The non-structural 3C protein is the protease that is responsible for most of the maturation events. The P1 precursor is processed by 3C protease into three structural proteins, VP1, VP3 and VP0, forming the FMDV protomer. The VP1 protein plays important roles in attachment, protective immunity and serotype specificity. VP1 is considered to be the major immunogenic protein, as it contains a linear antigenic site that is able to induce neutralizing antibodies that suffice to protect animals against the disease.In this project, we developed a novel vaccine against FMD, based on canine adenovirus type 2 (Cav2). In vitro evaluation of Cav2 mediated gene transfer in pigs and cattle showed that the Cav2 vector holds promise for the development of vaccines for pigs and cattle. Study of these recombinant viruses indicated that Cav2-FMDV supported expression of FMDV capsid proteins in vitro. The immunogenicity of these recombinant viruses was evidenced in mouse and guinea pig models, and encouraging results in guinea pigs suggested that the immune response elicited against FMD by recombinant virus could afford partial protection against FMDV challenge. In the future, immunization with Cav2-derived vector should be optimized to confirm these preliminary results. This type of vaccine, when designed to express capsid but not non-structural proteins of FMDV, can serve as a marker vaccine against FMD

The project was undertaken to monitor a group of 30 foals on a farm both clinically and microbiologically from birth until one year of age, to determine the aetiology of upper respiratory tract infections and to establish immune profiles of some of the known respiratory viral pathogens. One to two months prior to the birth of their foals, blood for serology was collected from the mares. The same specimens were collected from the foals just after birth, prior to suckling and a day after suckling. Thereafter the foals were examined monthly for the presence of respiratory disease and specimens taken. The following specimens were collected from each foal: three nasopharyngeal swabs, (one for virus isolation, one for bacteria and fungus isolation, and one for mycoplasma isolation) and blood that was allowed to clot. Blood was collected in heparin from sick foals with elevated rectal temperatures. Virus isolation was done on roller tube cultures of equine embryonic lung (EEL), Vero cells and rabbit kidney 13 (RK13) cells. The bacteria (including mycoplasmas) and fungi were cultured from the swabs and identified using a variety of traditional methods. The serum neutralization test (SNT) was used to detect antibodies to equid herpesvirus 1 (EHV-1), equid herpesvirus 4 (EHV-4), equine rhinovirus 1 (ERV-1), equine rhinovirus 2 (ERV-2) and equine adenovirus 1 (EAdV-1). The complement fixation test (CFT) was used to detect antibodies to EHV-1 and EHV-4 and the haemagglutination inhibition test (HIT) antibodies to equine influenzavirus (EIV). Only EHV-4 was cultured from the nasopharyngeal swabs of nine foals when they were 5 to 6 months of age and from one foal two months later. A wide variety of bacteria and fungi were cultured and it was established that coagulase-negative staphylococci, viridans streptococci, Moraxella spp. and Flavobacterium spp. predominated in most of the samples. Several potential bacterial pathogens were isolated but the most common were Streptococcus equi subsp. zooepidemicus, Actinobacillus equuland Staphylococcus aureus. Colostrum-derived antibodies were detected for all the viruses in all but two of the foals. It was found that the foals had similar or slightly higher titres than their mothers. The levels declined in direct proportion to what they initially were and were depleted by the time the foals were 2 to 7 months of age. Antibodies to natural infection was detected to EHV-4, ERV-2 and EAdV-1. A rise in antibody titres occurred when the foals were 5 to 6 months of age, two months later and when they were one year of age. Antibodies resulting from immunization was detected to EHV-1, EHV-4 and EIV. It was established that the most important virus causing upper respiratory tract disease of the foals from 5 to 12 months of age was EHV-1 with EAdV-1 playing a minor role. These viruses caused repeated bouts of infection with a two to five months interval. Streptococcus equi subsp. zooepidemicus was considered to be the most important secondary pathogen. Prior to this period most of the foals were healthy with only a few suffering from upper respiratory disease. The aetiology was not determined in these cases, but based on the bacteriology results, it was suspected that some of them were suffering from bacterial infections.
Dissertation (MSc (Veterinary Science))--University of Pretoria, 2005.
Veterinary Tropical Diseases
unrestricted

Conselho Nacional de Desenvolvimento Científico e Tecnológico
The objective of this study is to evaluate the adjuvant effect of interferon alpha (IFNα) in swine vaccinated with a recombinant replication-defective adenovirus containing foot-and-mouth disease virus (FMDV) protein coding regions, as well as to understand the molecular mechanisms involved in the interaction of FMDV with its host. In the first part of this thesis, the adjuvant effect of pIFNα was evaluated in swine vaccinated with a recombinant vaccine delivered by a human adenovirus type 5 (Ad5) vector containing FMDV capsid (P1-2A) and 3Cpro proteinase coding regions (Ad5-A24). Swine were separated into 5 groups and inoculated with low (5x108 PFU) or high (5x109 PFU) doses of Ad5-A24 in the presence or absence of pIFNα (Ad5-pIFN, 109 PFU). Control animals received 6x109 PFU of an Ad5 vector containing the glycoprotein gene of vesicular stomatitis virus (Ad5-VSNJV-G). All swine were challenged at 42 days post vaccination (dpv) with FMDV-A24. Prior to challenge, blood samples were examined for IFN production, induction of IFN-induced genes (ISG s), FMDV-specific neutralizing antibodies and FMDV-specific antibody isotypes. After challenge, a number of parameters were analyzed including clinical score, viremia, lymphopenia and antibodies against FMDV structural (S) and non-structural (NS) proteins. The results indicate that both groups that received high-dose Ad5-A24 developed an FMDV-specific neutralizing antibody response by 14-21 dpv, which was maintained until the day of challenge. Both high-dose groups developed high levels of IgG1 and IgG2, however the IgG1 response was higher. The high-dose Ad5-A24 with IFN group developed higher levels of IgG1 than the group administered only high-dose Ad5-A24 and this difference was statistically significant. Antiviral activity and IFNα were detected in the groups that received IFN. The three ISG s examined, PKR, OAS and Mx1, were detected by real time RT-PCR in leukocytes from Ad5-pIFNα-vaccinated swine. After challenge, all animals in the control group developed early viremia, vesicular lesions, considerable lymphopenia and antibodies to FMDV NS proteins. The animals that received low-dose Ad5-A24 without IFN had similar clinical signs, except that fewer animals had viremia. In contrast, pigs inoculated with the low-dose Ad5-A24 and IFNα had a delayed onset of vesicular lesions and only one animal had detectable viremia. Animals vaccinated with high-dose Ad5-A24 without IFNα had no viremia, showed fewer lesions, one animal had no lesions, and delayed onset of disease compared to the low-dose Ad5-A24 groups. Four of five pigs vaccinated with high-dose Ad5-A24 and IFNα were completely protected from disease and only one animal in this group had a vesicular lesion restricted to the site of challenge virus inoculation. The results indicate that IFNα enhances the level of protection induced by the Ad5-FMD vaccine against homologous FMDV, supporting the use of IFNα as a potential adjuvant in FMD vaccination strategies. To investigate the effect of FMDV infection on the induction of the host IFN-α/β response, swine cells were infected with wild-type (WT) FMDV and a mutant FMDV lacking the L proteinase (Lpro) coding region (A12-LLV) at different multiplicities of infection. The synthesis of IFN-α and IFN-β mRNAs and three well characterized ISG s, PKR, OAS, and Mx1 mRNA, were evaluated by real time RT-PCR. A12-LLV infection resulted in significantly higher levels of induction of IFN-β mRNA as compared to WT virus infected cells, while IFN-α mRNA was not induced after either infection. The increased levels of IFN-β mRNA in A12-LLV-infected cells correlated with higher levels of induction of PKR, OAS and Mx1 mRNAs and antiviral activity. By using RNA interference (RNAi) technology to knock-down PKR mRNA expression, it was possible to demonstrate that the yield of A12-LLV was increased up to 200-fold, supporting the role of PKR as an inhibitor of FMDV replication. These results confirm that Lpro down regulates the innate immune response to FMDV infection at multiple levels. Previous studies indicated that control was at the translation initiation level by Lpro cleavage of translation initiation factor eIF-4G. The present data demonstrates that regulation also occurs at the level of transcription by inhibition of IFN-β mRNA induction through an unknown mechanism.
Esse trabalho tem como objetivo avaliar o efeito adjuvante do interferon alfa suíno em animais imunizados com uma vacina recombinante de um adenovírus defectivo contendo as regiões codificadoras das proteínas do FMDV, bem como investigar alguns dos aspectos moleculares envolvidos na interação FMDV e a célula hospedeira em uma espécie susceptível. Na primeira fase do trabalho, o efeito adjuvante do interferon alfa suíno (pIFNα) foi avaliado em suínos imunizados com uma vacina recombinante, tendo como vetor o adenovirus humano tipo 5 (Ad5), contendo regiões do capsídeo do FMDV A24 e da proteinase 3Cpro do FMDV A12 (Ad5-A24). Os suínos foram separados em 5 grupos e inoculados com baixa (5x108 PFU) e alta (5x109 PFU) dosagem de Ad5-A24 na presença ou na ausência de pIFNα (Ad5pIFNα, 109 PFU). O grupo controle foi inoculado com 6x109 PFU da glicoproteína do vírus da estomatite vesicular (VSV) cepa New Jersey (Ad5VSNJV-G). Todos os suínos foram desafiados aos 42 dias pós-vacinação (dpv) com FMDV-A24. Após a inoculação, as amostras de sangue foram examinadas para a produção de IFN, a indução de genes induzidos pelo IFN e os anticorpos neutralizantes e resposta de imunoglobulinas específicos para o FMDV. Depois do desafio um número de parâmetros foram analisados incluindo a avaliação clínica, viremia, linfopenia; além dos anticorpos contra as proteínas estruturais e não estruturais do FMDV. Os resultados obtidos indicam que ambos os grupos que receberam Ad5-A24 em alta dosagem desenvolveram níveis de anticorpos neutralizantes pelos 14-21 dpv, que foram mantidos até o dia do desafio. Os níveis de IgG1 foram maiores que de IgG2 nesses dois grupos, sendo que a IgG1 é considerada a mais relevante para conferir proteção ao FMDV. Dentre esses grupos, o que recebeu o IFN apresentou níveis significativamente mais altos desta imunoglobulina. Atividade antiviral e o IFNα foram detectados nos animais que receberam o IFN. A respeito da presença dos genes induzidos pelo IFN nos leucócitos dos suínos vacinados com Ad5-pIFNα, todos os três genes incluídos neste estudo, PKR, OAS e Mx1, foram detectados pelo real time RT-PCR. Após o desafio todos os animais do controle desenvolveram viremia, linfopenia, lesões vesiculares e os anticorpos contra as proteínas não estruturais do FMDV. Os animais que receberam baixa dose de Ad5-A24 sem IFN tiveram sinais clínicos similares, exceto que poucos animais desenvolveram viremia. Porém, os suínos inoculados com a mesma dose da vacina de Ad5-A24 com o IFN apresentaram as lesões vesiculares com início tardio e somente um animal teve detectável viremia. Os animais vacinados com a alta dose de Ad5-A24 sem IFN não tiveram nenhuma viremia e poucas lesões foram detectadas tardiamente após a inoculação do FMDV. Quatro dos cinco suínos, que receberam a alta dose da vacina com o IFN, foram protegidos da doença e somente um animal neste grupo teve uma lesão vesicular, restrita ao local do inoculação do vírus por ocasião do desafio. Esses resultados indicam que IFNα realça o nível da proteção induzido pela vacina do adenovírus-FMD contra o FMDV homólogo, suportando o uso do IFNα como um adjuvante potencial em estratégias de vacinação de FMD. Para avaliar os efeitos da infecção pelo vírus da FMD na indução da resposta de IFNα⁄β do hospedeiro, células de origem suína foram previamente infectadas em diferentes multiplicidades de infecção com o FMDV e com um vírus mutante que teve o gene que codifica a protease L ou Lpro deletado, o FMDLLV. A síntese de mRNA do IFNα e β bem como de três dos genes induzidos pelo IFN, PKR, OAS e Mx1 foram avaliados por real time RT-PCR. A infecção das células pelo FMDLLV induziu altos níveis de mRNA do IFNβ quando comparados com os do FMDV original. Contudo, não foi possível detectar os níveis de mRNA do IFNα na presença de ambos os vírus. O aumento nos níveis de mRNA do IFNβ foi relacionado ao aumento nos níveis de indução dos mRNAs de PKR, OAS e Mx1, assim como dos altos níveis de atividade antiviral. Pelo uso da tecnologia de interferência do RNA, usando siRNA (silencing RNA) para bloquear a expressão do mRNA da PKR, foi possível demonstrar que o título do FMDLLV aumentou cerca de 200 vezes. Desta forma foi possível confirmar o papel desta proteína como um inibidor da replicação do FMDV. Os resultados obtidos demonstram que a Lpro tem um importante papel na regulação da resposta imunológica inata do hospedeiro quando da infecção pelo FMDV em vários níveis. Estudos anteriormente realizados indicaram que o controle era efetuado ao nível da tradução pela clivagem do eIF4G. Os dados obtidos neste trabalho indicam que a regulação também ocorre ao nível da transcrição e pela inibição da indução do IFNβ através de um mecanismo ainda não conhecido.

Introduction: Epidemiological studies have indicated that 5-38% of influenza like illnesses (ILI) develop into severe disease due to, among others, factors such as; underlying chronic diseases, age, pregnancy, and viral mutations. There are suggestions that dual or multiple virus infections may affect disease severity. This study investigated the association between co-infection between influenza A viruses and other respiratory viruses and disease severity. Methodology: Datum for samples from North West England tested between January 2007 and June 2012 was analysed for patterns of co-infection between influenza A viruses and ten respiratory viruses. Risk of hospitalization to a general ward ICU or death in single versus mixed infections was assessed using multiple logistic regression models. Results: One or more viruses were identified in 37.8% (11,715/30,975) of samples, of which 10.4% (1,214) were mixed infections and 89.6% (10,501) were single infections. Among patients with influenza A(H1N1)pdm09, co-infections occurred in 4.7% (137⁄2,879) vs. 6.5% (59⁄902) in those with seasonal influenza A virus infection. In general, patients with mixed respiratory virus infections had a higher risk of admission to a general ward (OR: 1.43, 95% CI: 1.2 – 1.7, p = <0.0001) than those with a single infection. Co-infection between seasonal influenza A viruses and influenza B virus was associated with a significant increase in the risk of admission to ICU/ death (OR: 22.0, 95% CI: 2.21 – 219.8 p = 0.008). RSV/seasonal influenza A viruses co-infection also associated with increased risk but this was not statistically significant. For the pandemic influenza A(H1N1)pdm09 virus, RSV and AdV co-infection increased risk of hospitalization to a general ward, whereas Flu B increased risk of admission to ICU/ death, but none of these were statistically significant. Considering only single infections, RSV and hPIV1-3 increased risk of admission to a general ward (OR: 1.49, 95% CI: 1.28 – 1.73, p = <0.0001 and OR: 1.34, 95% CI: 1.003 – 1.8, p = 0.05) and admission to ICU/ death (OR: 1.5, 95% CI: 1.20 – 2.0, p = <0.0001 and OR: 1.60, 95% CI: 1.02 – 2.40, p = 0.04). Conclusion: Co-infection is a significant predictor of disease outcome; there is insufficient public health data on this subject as not all samples sent for investigation of respiratory virus infection are tested for all respiratory viruses. Integration of testing for respiratory viruses’ co-infections into routine clinical practice and R&D on integrated drugs and vaccines for influenza A&B, RSV, and AdV, and development of multi-target diagnostic tests is encouraged.

Six 3 to 4 weeks old, cesarian-derived lambs were inoculated with ovine an adenovirus isolate 475N. Inoculated lambs showed moderate clinical signs of respiratory distress, conjunctivitis, and loose feces during the 10-day observation period. Virus was detected from nasal and conjunctival swabs starting on postinoculation day (PID) 2. Virus was detected in the feces in a inconsistent fashion. At necropsy, virus was present in the lung, tonsils, and bronchial and mediastinal lymph nodes of lambs necropsied on PID 5 and 7. Tissue samples from gastrointestinal tract and kidney were negative for the virus. Presence of virus in the feces was believed to be from replication in tonsillar tissue. At necropsy, lambs showed signs of pneumonia and numerous intranuclear inclusion bodies were detected in affected lung tissue. Virus neutralizing antibodies appeared at low levels in serum on PID 6 and reached higher levels by PID 10. Six ovine adenovirus prototype species, three uncharacterized ovine and bovine adenoviruses isolates and two uncharacterized llama adenoviruses isolates were digested with four different restriction enzymes. Digested viral DNA was separated in 0.7% agarose gels. The enzymes Barn HI, Eco RI, Hind III, and Pst I digested viral DNA and produced 2-10 bands. The profile of the band distribution permitted the differentiation of the viruses under study. However, further studies using multiple isolates of each species are required to determine if this procedure will efficiently distinguish different species of ruminant adenoviruses. Ten adenoviruses from sheep (including the six prototype species), one from bovine and one from llama were studied by virus neutralization test to determine their degree of antigenic similarities. Reciprocal virus neutralization tests were performed and the degree of antigenic similarities, i.e., strain differentiation was determined by criteria established by the International Committee for the Nomenclature of Viruses. Isolates 32CN (a bovine adenovirus) and 475N (an ovine adenovirus) were antigenically identical and not neutralized by any of the prototype species antiserum. They are candidates for a new species of ruminant adenoviruses. Ovine adenovirus isolate 47F was shown to be a member of OAV-5 species while the llama adenovirus strain represents a newly recognized species for this animal.
Graduation date: 1996

First in 1997, and later re-emerging in 2003, highly pathogenic avian influenza A virus, subtype H5N1, has spread from wild bird reservoirs to domestic bird flocks. As a result, cross-transmission has been confirmed in people living or working in close contact with infected birds. H5N1 virus infection is associated with a high mortality rate (>60%) in humans and the rapid evolution of the virus suggests that it could potentially develop into a new, and possibly severe, pandemic influenza virus. To-date, conventional inactivated and live-attenuated vaccine strategies offers the best protection against influenza virus infection; however, poor immunogenicity and weaker efficacy have been observed against H5N1 viruses. It was hypothesized that experimental adenovirus-based vaccines based on human adenovirus serotype 5 (AdHu5) or porcine adenovirus serotype 3 (PAV3) can offer protection against a broad range of avian influenza, subtype H5N1, viruses. Ad vaccine vectors are highly immunogenic and have demonstrated protective efficacy against several disease models. However, natural immunity against AdHu5 can interfere with vector efficacy. The nonhuman PAV3 was not neutralized by pooled human serum from 10,000-60,000 individuals and offers a promising alternative to AdHu5-based vectors. Systematic antigen screening using DNA vaccines identified the hemagglutinin (HA) glycoprotein as the most immunogenic H5N1 antigen. HA was then inserted directly into PAV3 or AdHu5. Comparable immune responses were observed between both vectors but, interestingly, the PAV3-based vaccine generated stronger T-cell responses and better rapid protection 8 days following immunization. Additionally, better long-term protection 1 year following vaccination was observed with the PAV3-HA vaccine. The co-administration of multiple H5N1 antigens was also screened to improve protection against divergent H5N1 challenge. Combinations of DNA vaccines expressing (HA+NA) and (HA+NP) offered the best promise for enhancing protection against homologous and heterologous H5N1 challenges, respectively. However, addition of three or more antigens reduced overall protection possibly by antigen dilution, competition, or interference. Co-administration of PAV3 or AdHu5 vectors expressing both the HA and NP antigens reduced protection against homologous and heterologous H5N1 virus challenges. For all combination vaccines, T-cell responses were strong against HA but significantly decreased against additional antigens in each combination vaccine. Overall, the experimental porcine-based Ad-based vaccine offered better protection than the H5N1 conventional vaccine against a broad range of different H5N1 viruses. Understanding of the relationship between immune parameters and protection will be critical in future improvement of adenovirus-based and other vaccines against avian influenza H5N1.

Thesis (Ph.D.) -- University of Adelaide, School of Paediatrics and Reproductive Health, Discipline of Paediatrics, 2007.
"June 2007" Includes Addenda attached to back page. Bibliography: leaves 215-274. Also available in print form.

The coxsackie-adenovirus receptor (CAR) is a viral receptor for Group B coxsackieviruses (CVB). Physiologically, CAR is a cellular adhesion protein. I report that upregulation of cardiac CAR in the young adult mouse (CAR+/MtTA+ ) caused a cardiomyopathy that was characterized by inflammation and hypertrophy. In the hearts of CAR+/MtTA+ mice c-Jun N terminal kinase (JNK) was specifically activated. JNK activation is known to promote hypertrophy of cardiomyocytes, and disrupt proteins at the intercalated disc. CVB3-infected CAR+/MtTA+ mice did not exhibit increased cardiac viral load or myocarditis severity, but did demonstrate a greater cardiac interferon-γ (IFN-γ) response when compared to littermate controls. CAR-induced expression of this antiviral cytokine may have prevented the increase in myocarditis susceptibility. Further investigation into the activation of protein kinase signaling, and antiviral signaling will provide better understanding of how CAR participates in the pathogenesis of both viral and non-viral heart diseases.

Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomal-recessively inherited disorder caused by the deficiency of lysosomal sulphamidase (NS) enzyme activity, resulting in the accumulation of the glycosaminoglycan (GAG) heparan sulphate (HS). MPS IIIA patients experience progressive and severe neurological deterioration with death usually occurring in the mid-late teenage years. A naturally-occurring mouse model of MPS IIIA has been characterised and the biochemical, histological and behavioural changes closely parallel the human condition. In order to treat the neurological effects of MPS IIIA, it is anticipated that a continual supply of replacement enzyme to affected cells will be required. Consequently, this study aimed to evaluate the efficacy, longevity and safety of gene therapy as a potential treatment for MPS IIIA. Canine adenoviral vectors (CAV-2) were selected on the basis of several important properties. They are non-integrating, are predicted to be less immunogenic in humans than human-derived viral vectors and mediate transgene expression for at least 1 year in vivo. An E1-deleted (∆E1) CAV-2 vector, CAV-NS, co-expressing recombinant human NS (rhNS) and Green Fluorescent Protein (GFP) was constructed and purified. In vitro testing revealed rhNS produced by CAV-NS significantly decreased sulphated GAG storage in human MPS IIIA fibroblasts in a mannose-6-phosphate-dependent manner. Preliminary studies in young adult guinea pigs with CAV-GFP demonstrated widespread GFP expression in the absence of a humoral response. In contrast, minimal GFP expression was found in CAV-injected adult mice due to formation of neutralising antibodies against the CAV-2 capsid. Consequently, intraventricular delivery of CAV-NS was evaluated in newborn mice at various doses. Widespread and dose-dependent GFP expression was observed and the optimal dose for large-scale studies was determined to be 109 CAV-NS particles/hemisphere. Antibodies against CAV-2, rhNS or GFP were not detected. Concurrently, the cognitive function and anxiety-related behaviours of unaffected and MPS IIIA mice were evaluated. MPS IIIA mice had significantly impaired memory and spatial learning in the Morris Water Maze (16-wks) and reduced anxiety in the Elevated Plus Maze (18-wks) when compared to unaffected animals. In a large therapeutic assessment trial, newborn MPS IIIA or unaffected mice received 109 particles of CAV-NS, saline or remained uninjected. GFP expression was visualised for at least 20-wks post-injection. Reductions in the vacuolation of ependymal and choroidal cells of the lateral ventricle and the cerebral cortex of treated MPS IIIA animals were observed in some GFP-positive (and presumably rhNS-expressing) regions. Furthermore, improvements in reactive astrogliosis, but not in the number of activated microglia, were measured in CAVNS- treated MPS IIIA mice. However, insufficient CAV-NS-mediated rhNS expression was generated to improve functional changes as assessed by a behavioural test battery (motor function, open field activity, Elevated Plus Maze, Morris Water Maze), potentially due to chronic inflammatory responses against the CAV-2 vector. Collectively, these data suggest that early intervention with ∆E1 CAV-NS gene therapy was able to improve several components of neuropathology in MPS IIIA animals but was unable to significantly alter the clinical progression of murine MPS IIIA.
http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1295758
Thesis (Ph.D.) -- University of Adelaide, School of Paediatrics and Reproductive Health, 2007

Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomal-recessively inherited disorder caused by the deficiency of lysosomal sulphamidase (NS) enzyme activity, resulting in the accumulation of the glycosaminoglycan (GAG) heparan sulphate (HS). MPS IIIA patients experience progressive and severe neurological deterioration with death usually occurring in the mid-late teenage years. A naturally-occurring mouse model of MPS IIIA has been characterised and the biochemical, histological and behavioural changes closely parallel the human condition. In order to treat the neurological effects of MPS IIIA, it is anticipated that a continual supply of replacement enzyme to affected cells will be required. Consequently, this study aimed to evaluate the efficacy, longevity and safety of gene therapy as a potential treatment for MPS IIIA. Canine adenoviral vectors (CAV-2) were selected on the basis of several important properties. They are non-integrating, are predicted to be less immunogenic in humans than human-derived viral vectors and mediate transgene expression for at least 1 year in vivo. An E1-deleted (∆E1) CAV-2 vector, CAV-NS, co-expressing recombinant human NS (rhNS) and Green Fluorescent Protein (GFP) was constructed and purified. In vitro testing revealed rhNS produced by CAV-NS significantly decreased sulphated GAG storage in human MPS IIIA fibroblasts in a mannose-6-phosphate-dependent manner. Preliminary studies in young adult guinea pigs with CAV-GFP demonstrated widespread GFP expression in the absence of a humoral response. In contrast, minimal GFP expression was found in CAV-injected adult mice due to formation of neutralising antibodies against the CAV-2 capsid. Consequently, intraventricular delivery of CAV-NS was evaluated in newborn mice at various doses. Widespread and dose-dependent GFP expression was observed and the optimal dose for large-scale studies was determined to be 109 CAV-NS particles/hemisphere. Antibodies against CAV-2, rhNS or GFP were not detected. Concurrently, the cognitive function and anxiety-related behaviours of unaffected and MPS IIIA mice were evaluated. MPS IIIA mice had significantly impaired memory and spatial learning in the Morris Water Maze (16-wks) and reduced anxiety in the Elevated Plus Maze (18-wks) when compared to unaffected animals. In a large therapeutic assessment trial, newborn MPS IIIA or unaffected mice received 109 particles of CAV-NS, saline or remained uninjected. GFP expression was visualised for at least 20-wks post-injection. Reductions in the vacuolation of ependymal and choroidal cells of the lateral ventricle and the cerebral cortex of treated MPS IIIA animals were observed in some GFP-positive (and presumably rhNS-expressing) regions. Furthermore, improvements in reactive astrogliosis, but not in the number of activated microglia, were measured in CAVNS- treated MPS IIIA mice. However, insufficient CAV-NS-mediated rhNS expression was generated to improve functional changes as assessed by a behavioural test battery (motor function, open field activity, Elevated Plus Maze, Morris Water Maze), potentially due to chronic inflammatory responses against the CAV-2 vector. Collectively, these data suggest that early intervention with ∆E1 CAV-NS gene therapy was able to improve several components of neuropathology in MPS IIIA animals but was unable to significantly alter the clinical progression of murine MPS IIIA.
Thesis (Ph.D.) -- University of Adelaide, School of Paediatrics and Reproductive Health, 2007

Title page, contents and abstract only. The complete thesis in print form is available from the University of Adelaide Library.
The development of gene therapy for clinical use continues to face many hurdles. A major issue is the limitation of gene delivery technology. This body of work describes strategies for improving the selectivity and efficacy of gene delivery to vascular endothelium, with emphasis on delivery to pulmonary vasculature in vivo. Several important principles were established which continue to be of relevance to the field. The work progresses from vector development through to the use of new vector strategies in the application of novel gene delivery approaches in disease models. Work in gene therapy and vector development began in the Division of Human Gene Therapy, University of Alabama at Birmingham, under the mentorship of Prof David T Curiel and has continued through international collaborations and the establishment of my own laboratory in the Hanson Institute with affiliate links to the University of Adelaide. The work presented in this thesis consists entirely of published material, either as book chapters (three) or peer reviewed journal articles (twelve). The sequence of material progresses from a broad introduction to the field on Gene Therapy, more specific chapters dealing with pulmonary gene delivery including a detailed methodology chapter. The peer reviewed works contain an evolution of work dealing with the development of strategies to target adenoviral gene delivery vectors to the pulmonary vascular endothelium. This work encompasses the use of bi-specific conjugates, genetic modification of viral capsid (outer coat) proteins and the use of cell-specific promoters. The work progresses to a demonstration of the therapeutic gains achieved with the use of targeted over non-targeted vectors in animal models and culminates with a highly novel application of modulation of the bone morphogenetic protein pathway in pulmonary hypertension. A component of the work focuses on enhanced gene delivery to vein grafts exVIVO. There are many key original contributions encompassed within the work, including 1) first use of conjugate-based retargeting to vascular cells, 2) first demonstration that tropism modification could alter in vivo biodistribution of virus, 3) first demonstration of cell-specific retargeting of adenoviral vector after systemic vascular injection in vivo (a technique still unsurpassed in the field), 4) first demonstration of the in vivo selectivity gains achieved by combined cell-specific promoters with viral retargeting, 5) first demonstration of therapeutic gains achieved by targeting in a vascular context and 6) first demonstration that modulation of the BMPR2 pathway can have a therapeutic impact in pulmonary hypertension. Importantly, the targeting work I have developed has been adapted and used by others and laid a foundation for further vector improvements.
http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1349837
Thesis (M.D.) -- University of Adelaide, School of Medicine, 2009

Hepatocellular carcinoma (HCC) is the third commonest cancer worldwide. However HCC is considered to be highly resistant to chemotherapy. Gene therapies aimed to regulate Bd-2 proteins may sensitize HCC cells to chemotherapy. Studies have demonstrated that Bid/tBid are crucial in hepatocyte apoptosis. Bid also plays important roles in the development and chemotherapeutic sensitivity of HCC. The objective of this study is to test effect of Ad/AFPtBid and chemotherapeutic agents in combination on an orthotopic HCC model.
In conclusion, (1) Ad/AFPtBid can specifically target and effectively suppress the AFP-producing HCC. (2) Ad/AFPtBid can significantly sensitize HCC to 5-FU, their combination can significantly increase the anti-tumor effectiveness. (3) Ad/AFPtBid shows little toxicity in vivo. (4) The complementary effect of tBid and 5-FU on different phases of the cell cycle may explain the better therapeutic result if both are used to treat HCC. (5) The elucidation of phase specific effect of tBid points to a possible therapeutic option that combines tBid with different phase specific agents to treat HCC.
It is well established that many apoptosis inducers act in a cell cycle-specific fashion. This leads us to hypothesize that tBid might have phase specific effect. So, we tested the susceptibility of Hep3B cells at 00/01, S or G2/M phases to tBid. The results revealed that tBid significantly reduced Hep3B cells in G0/G1 phase, increased cells in G2/M phase. On the contrary, 5-FU arrested Hep3B cells in G0/G1 phase, and significantly reduced cells in G2/M phase. The levels of cell cycle-related proteins were altered in line with the result of the cell cycle. This suggests Hep3B cells in G0/G1 phase may be more susceptible to tBid. The complementary effects tBid and 5-FU on different phases of the cell cycle may explain the better therapeutic result if both are used to treat HCC.
The mice bearing orthotopic HCC tumors were treated with Ad/AFPtBid alone or in combination with 5-FU/Dox. Serum AFP levels were measured to mornitor tumor progression. The mice were killed four weeks after treatment. Liver tissues were subjected to immunohistochemical staining of proliferation cell nuclear antigen (PCNA) and TUNEL staining. Another batch of mice was observed for survival rate over a six month period. In addition, possible side effects of Ad/AFPtBid were tested in BALB/c mice. Results demonstrated that Ad/AFPtBid significantly inhibited Hep3B tumor growth. The combination of Ad/AFPtBid with 5-FU was more effective in tumor regression than either agent alone. However, the combination of Ad/AFPtBid with Dox treatment failed to demonstrated better effect than Dox treatment alone because the mice that received Dox exhibited serious weight loss. Tumor tissues from Ad/AFPtBid alone or combination treatment groups showed a decrease in cells positive for PCNA, and an increase in apoptosis by TUNEL staining, indicating that Ad/AFPtBid induced tumor regression through its pro-apoptotic effect. Inflammatory cell infiltration was also increased. Furthermore, Ad/AFPtBid did not suppress the hepatic tumor formed by non-AFP producing SK-HEP-1 or DLD-1. Finally, Ad/AFPtBid and 5-FU in combination results in better survival rate. No acute toxic effect of Ad/AFPtBid was observed.
Ma, Shihong.
"December 2009."
Adviser: CHEN Gong George.
Source: Dissertation Abstracts International, Volume: 72-01, Section: B, page: .
Thesis (Ph.D.)--Chinese University of Hong Kong, 2010.
Includes bibliographical references (leaves 114-138).
Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.
Electronic reproduction. Ann Arbor, MI : ProQuest Information and Learning Company, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web.
Abstract also in Chinese.